NGEN NervGen Pharma Corp. Common stock
Healthcare$2.08-43.48%ClosedMarket Cap: $168.3M
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
108.37
P/S
0.00
EV/EBITDA
-15.42
DCF Value
$0.25
FCF Yield
-4.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-17536.8%
ROA
-190.1%
ROIC
-719.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-1.7M | $— |
| Q4 null | $0.00 | $-31.7M | $— |
| FY null | $0.00 | $-44.1M | $— |
| Q3 null | $0.00 | $-3.0M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
4 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Trading Activity
Insider Trades
View AllSCHREIBER DAVIDdirector
SellTue Jul 01
Dreismann Heinerdirector
SellTue Jul 01
BIRNDORF HOWARD Cdirector, officer: Executive Chairman and CEO
SellWed Apr 23
SCHREIBER DAVIDdirector
SellFri Jun 15
Dreismann Heinerdirector
SellFri Jun 15
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.88
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.